BioAtla Reports $69.8 Million Net Loss in 2024 with Promising Clinical Development Progress
BioAtla, Inc. (NASDAQ: BCAB), a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor treatments, reported a net loss of $69.8 million for the fiscal year ended December 31, 2024. This represents a significant improvement from the $123.5 …